TPN171 is potent PDE5 inhibitor with subnanomolar potency for PDE5 and good selectivity over PDE6. TPN171 is a Clinical Candidate for the Treatment of Pulmonary Arterial Hypertension. TPN171 was proven to exert a longer lasting effect than sildenafil in animal models, providing a foundation for a once-daily oral administration for its clinical use.